Quick Takeaways
- LYEL - Lyell Immunopharma, Inc. has 25 insiders with reported activity on this page.
- Net insider value flow over the last year: +$24,513,700.
- Recent transaction rows are available for direct filing-level review.
- Info
- Insider Trading
- Financials
- Holders: LYEL, LYEL
Insider Transactions Reported by 25 Insiders of Lyell Immunopharma, Inc.
- Symbol
- LYEL on Nasdaq
- Location
- South San Francisco, CA
What Changed
- Buy value: $24,999,970; sell value: $486,269.
- Net share flow: +949,231.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Official SEC Source
Insider trading overview
Last 12 monthsNet insider flow leans to buying over the last 12 months. Net value: +$24,513,700.
Buys
$24,999,970
Shares: 976,180
Insiders: 2
Sells
$486,269
Shares: 26,949
Insiders: 5
Net
+$24,513,700
Shares: +949,231
Insiders: -3
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 976,180 | 11,310 | $24,999,970 | $264,285 | +$24,735,685 |
| 3-6 | 0 | 2,956 | $0 | $88,427 | -$88,427 |
| 6-9 | 0 | 12,683 | $0 | $133,557 | -$133,557 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Lyell Immunopharma, Inc. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Robert Nelsen | Director, 10%+ Owner | $83,020,992 | Mixed | 14 Jun 2024 | ||
| GSK plc | 10%+ Owner | $68,977,271 | Mixed | 21 Jun 2021 | ||
| ARCH Venture Partners IX, LLC | 10%+ Owner | $36,533,382 | +$12,499,985 | +52% | Filing P/S | 06 Mar 2026 |
| ARCH Venture Fund XIII, L.P. | 10%+ Owner | $36,533,382 | +$12,499,985 | +52% | Filing P/S | 06 Mar 2026 |
| Hans Edgar Bishop | Director | $10,683,200 | Mixed | 14 Jun 2024 | ||
| Richard Klausner | Director | $1,791,262 | Mixed | 15 May 2025 | ||
| Lynn Seely | President and CEO, Director | $1,737,081 | -$275,967 | -14% | Filing P/S | 11 Feb 2026 |
| David Shook | Chief Medical Officer | $519,249 | Mixed | 10 Feb 2026 | ||
| Stephen J. Hill | Chief Operating Officer | $416,225 | -$45,477 | -9.8% | Filing P/S | 11 Feb 2026 |
| Gary K. Lee | Chief Scientific Officer | $396,179 | -$62,819 | -14% | Filing P/S | 11 Feb 2026 |
| Veronica Sanchez Bulis | VP, Corporate Controller | $361,527 | -$83,901 | -19% | Filing P/S | 10 Feb 2026 |
| Charles W. Newton | Chief Financial Officer | $290,086 | -$18,105 | -5.9% | Mixed | 20 Aug 2025 |
| Cathy Friedman | Director | $158,093 | Mixed | 15 May 2025 | ||
| Matthew Lang | Chief Business Officer | $114,000 | Mixed | 10 Feb 2025 | ||
| Sumant Ramachandra | Director | $94,000 | Mixed | 15 May 2025 | ||
| Dr. Otis W. Brawley | Director | $16,750 | Mixed | 15 May 2025 | ||
| Tina M. Albertson | Chief Medical Officer | $9,232 | Mixed | 24 Feb 2023 | ||
| Mark Bachleda | Director | Mixed | 09 Jun 2025 | |||
| Mark A. Meltz | General Counsel | Mixed | 10 Feb 2026 | |||
| Rahsaan W. Thompson | Chief Legal Officer | Mixed | 24 Feb 2023 | |||
| Smital Shah | Chief Fin. and Bus. Officer | Mixed | 09 Mar 2026 | |||
| Elizabeth Homans | Chief Executive Officer, Director | Mixed | 16 Mar 2022 | |||
| William Jl Rieflin | Director | Mixed | 15 May 2025 | |||
| Elizabeth G. Nabel | Director | Mixed | 15 May 2025 | |||
| Heather D. Turner | Chief General Counsel | Mixed | 16 Mar 2022 |
Top shareholders of Lyell Immunopharma, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| ARCH Venture Management, LLC |
13F
|
Company |
14%
|
2,759,072
|
$84,924,236 | — | 31 Dec 2025 | |
| Robert Nelsen |
3/4/5
|
Director, 10%+ Owner |
—
mixed-class rows
|
36,542,716
mixed-class rows
|
$83,020,992 | — | 14 Jun 2024 | |
| GSK plc |
3/4/5
13F
|
10%+ Owner · Company |
7.9%
from 13F
|
30,253,189
|
$68,977,271 | — | 21 Jun 2021 | |
| ARCH Venture Fund IX, L.P. |
13D/G
|
— |
13%
|
2,759,072
|
$44,807,053 | $0 | 30 Sep 2025 | |
| ARCH Venture Fund XIII, L.P. |
3/4/5
|
10%+ Owner |
7.5%
|
1,426,528
|
$36,533,382 | +$12,499,985 | 06 Mar 2026 | |
| ARCH Venture Partners IX, LLC |
3/4/5
|
10%+ Owner |
7.5%
|
1,426,528
|
$36,533,382 | +$12,499,985 | 06 Mar 2026 | |
| MWG Caph Ltd |
13F
|
Company |
5.3%
|
1,008,116
|
$31,029,810 | — | 31 Dec 2025 | |
| Innovative Cellular Therapeutics Holdings Ltd |
13D/G
|
— |
9.8%
|
1,900,000
|
$30,855,810 | $0 | 06 Nov 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
4.3%
|
826,430
|
$25,437,516 | — | 31 Dec 2025 | |
| Foresite Capital Management IV, LLC |
13F
|
Company |
4.2%
|
800,399
|
$24,636,281 | — | 31 Dec 2025 | |
| Foresite Capital Fund IV, L.P. |
13D/G
|
James B. Tananbaum |
7.6%
|
1,454,616
|
$23,622,818 | $0 | 30 Sep 2025 | |
| Orland Properties Ltd |
13F
|
Company |
3.9%
|
754,698
|
$23,229,604 | — | 31 Dec 2025 | |
| Decheng Capital LLC |
13F
|
Company |
3.6%
|
692,050
|
$21,301,299 | — | 31 Dec 2025 | |
| Almitas Capital LLC |
13F
|
Company |
3%
|
577,807
|
$17,784,899 | — | 31 Dec 2025 | |
| Foresite Capital Management V, LLC |
13F
|
Company |
2.5%
|
477,078
|
$14,684,461 | — | 31 Dec 2025 | |
| NEWTON (PTC) Ltd |
13D/G
|
Newton (PTC) Limited |
3.9%
|
754,698
|
$12,256,220 | $0 | 30 Sep 2025 | |
| Hans Edgar Bishop |
3/4/5
|
Director |
—
mixed-class rows
|
4,815,614
mixed-class rows
|
$10,683,200 | — | 14 Jun 2024 | |
| Gates Frontier, LLC |
13D/G
|
— |
5.6%
|
1,040,964
|
$10,628,242 | $0 | 25 Jul 2025 | |
| venBio Partners LLC |
13F
|
Company |
1.8%
|
337,697
|
$10,394,314 | — | 31 Dec 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
1.7%
|
324,701
|
$9,994,297 | — | 31 Dec 2025 | |
| Explore Investments LLC/DE |
13D/G
|
Explore Investments LLC |
5.4%
|
1,040,964
|
$9,202,122 | $0 | 25 Jul 2025 | |
| Alphabet Inc. |
13F
|
Company |
1.5%
|
293,256
|
$9,026,420 | — | 31 Dec 2025 | |
| BlackRock, Inc. |
13D/G
13F
|
Company |
4.5%
|
13,265,869
|
$6,234,958 | $0 | 31 Dec 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.85%
|
162,997
|
$5,019,879 | — | 31 Dec 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.79%
|
151,016
|
$4,648,272 | — | 31 Dec 2025 | |
| HSG Holding Ltd |
13F
|
Company |
0.8%
|
152,299
|
$3,935,406 | — | 31 Dec 2025 | |
| Invesco Ltd. |
13F
|
Company |
0.52%
|
98,649
|
$3,036,416 | — | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.51%
|
96,675
|
$2,975,657 | — | 31 Dec 2025 | |
| MIC Capital Management UK LLP |
13F
|
Company |
0.45%
|
87,028
|
$2,678,722 | — | 31 Dec 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.45%
|
85,423
|
$2,629,320 | — | 31 Dec 2025 | |
| RBF Capital, LLC |
13F
|
Company |
0.39%
|
74,585
|
$2,295,726 | — | 31 Dec 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.38%
|
73,315
|
$2,256,635 | — | 31 Dec 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.31%
|
58,651
|
$1,805,278 | — | 31 Dec 2025 | |
| Richard Klausner |
3/4/5
|
Director |
—
mixed-class rows
|
4,071,199
mixed-class rows
|
$1,791,262 | — | 15 May 2025 | |
| Lynn Seely |
3/4/5
|
President and CEO, Director |
—
mixed-class rows
|
229,266
mixed-class rows
|
$1,737,081 | -$275,967 | 11 Feb 2026 | |
| JOHNSON & JOHNSON |
13F
|
Company |
0.29%
|
54,887
|
$1,689,422 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.27%
|
51,472
|
$1,584,308 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.22%
|
42,949
|
$1,321,971 | — | 31 Dec 2025 | |
| Ikarian Capital, LLC |
13F
|
Company |
0.21%
|
41,081
|
$1,264,473 | — | 31 Dec 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.21%
|
39,490
|
$1,215,502 | — | 31 Dec 2025 | |
| CANADA PENSION PLAN INVESTMENT BOARD |
13F
|
Company |
0.17%
|
32,111
|
$988,377 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.16%
|
30,280
|
$932,019 | — | 31 Dec 2025 | |
| Susquehanna Portfolio Strategies, LLC |
13F
|
Company |
0.11%
|
20,800
|
$640,224 | — | 31 Dec 2025 | |
| Clarius Group, LLC |
13F
|
Company |
0.1%
|
19,958
|
$614,307 | — | 31 Dec 2025 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.09%
|
18,000
|
$554,040 | — | 31 Dec 2025 | |
| David Shook |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
71,900
mixed-class rows
|
$519,249 | — | 10 Feb 2026 | |
| BARCLAYS PLC |
13F
|
Company |
0.08%
|
15,967
|
$491,465 | — | 31 Dec 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.08%
|
15,616
|
$480,660 | — | 31 Dec 2025 | |
| Stephen J. Hill |
3/4/5
|
Chief Operating Officer |
—
mixed-class rows
|
82,795
mixed-class rows
|
$416,225 | -$45,477 | 11 Feb 2026 | |
| UBS Group AG |
13F
|
Company |
0.07%
|
13,203
|
$406,388 | — | 31 Dec 2025 |
Recent Insider Transactions by Companies or Individuals for Lyell Immunopharma, Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Smital Shah | LYEL | Option (right to buy) | Award | 140,000 | 140,000 | 09 Mar 2026 | Direct | |||
| ARCH Venture Partners IX, LLC | LYEL | Common Stock | Purchase | 52% | $12,499,985 | $25.61 | 488,090 | 1,426,528 | 06 Mar 2026 | See footnote |
| ARCH Venture Fund XIII, L.P. | LYEL | Common Stock | Purchase | 52% | $12,499,985 | $25.61 | 488,090 | 1,426,528 | 06 Mar 2026 | See footnote |
| Lynn Seely | LYEL | Common Stock | Sale | -9.12% | $174,372 | $23.39 | -7,455 | 74,266 | 11 Feb 2026 | Direct |
| Stephen J. Hill | LYEL | Common Stock | Sale | -6.49% | $28,910 | $23.39 | -1,236 | 17,795 | 11 Feb 2026 | Direct |
| Gary K. Lee | LYEL | Common Stock | Sale | -8.98% | $39,085 | $23.39 | -1,671 | 16,938 | 11 Feb 2026 | Direct |
| Stephen J. Hill | LYEL | Common Stock | Sale | -0.57% | $2,520 | $23.12 | -109 | 19,031 | 10 Feb 2026 | Direct |
| Stephen J. Hill | LYEL | Option (right to buy) | Award | 65,000 | 65,000 | 10 Feb 2026 | Direct | |||
| Gary K. Lee | LYEL | Common Stock | Sale | -0.78% | $3,399 | $23.12 | -147 | 18,609 | 10 Feb 2026 | Direct |
| Gary K. Lee | LYEL | Option (right to buy) | Award | 50,000 | 50,000 | 10 Feb 2026 | Direct | |||
| Lynn Seely | LYEL | Common Stock | Sale | -0.53% | $10,127 | $23.12 | -438 | 81,721 | 10 Feb 2026 | Direct |
| Lynn Seely | LYEL | Option (right to buy) | Award | 155,000 | 155,000 | 10 Feb 2026 | Direct | |||
| Mark A. Meltz | LYEL | Option (right to buy) | Award | 50,000 | 50,000 | 10 Feb 2026 | Direct | |||
| Veronica Sanchez Bulis | LYEL | Common Stock | Sale | -1.6% | $5,872 | $23.12 | -254 | 15,637 | 10 Feb 2026 | Direct |
| Veronica Sanchez Bulis | LYEL | Common Stock | Award | 122.5% | 8,750 | 15,891 | 10 Feb 2026 | Direct | ||
| David Shook | LYEL | Option (right to buy) | Award | 50,000 | 50,000 | 10 Feb 2026 | Direct | |||
| Stephen J. Hill | LYEL | Common Stock | Award | 26.4% | 4,000 | 19,140 | 09 Feb 2026 | Direct | ||
| Gary K. Lee | LYEL | Common Stock | Award | 27.1% | 4,000 | 18,756 | 09 Feb 2026 | Direct | ||
| Lynn Seely | LYEL | Common Stock | Award | 32.2% | 20,000 | 82,159 | 09 Feb 2026 | Direct | ||
| Veronica Sanchez Bulis | LYEL | Common Stock | Sale | -11.6% | $30,252 | $32.32 | -936 | 7,141 | 30 Dec 2025 | Direct |
| Veronica Sanchez Bulis | LYEL | Common Stock | Sale | -12.3% | $43,929 | $38.67 | -1,136 | 8,077 | 24 Dec 2025 | Direct |
| Veronica Sanchez Bulis | LYEL | Common Stock | Sale | -2.53% | $3,848 | $16.10 | -239 | 9,213 | 10 Nov 2025 | Direct |
| Gary K. Lee | LYEL | Common Stock | Sale | -0.89% | $2,230 | $16.16 | -138 | 15,366 | 10 Nov 2025 | Direct |
| Stephen J. Hill | LYEL | Common Stock | Sale | -0.6% | $1,531 | $16.12 | -95 | 15,750 | 10 Nov 2025 | Direct |
| Lynn Seely | LYEL | Common Stock | Sale | -0.61% | $6,637 | $16.11 | -412 | 67,159 | 10 Nov 2025 | Direct |
| Stephen J. Hill | LYEL | Option (right to buy) | Award | 75,000 | 75,000 | 27 Oct 2025 | Direct | |||
| Gary K. Lee | LYEL | Option (right to buy) | Award | 68,000 | 68,000 | 27 Oct 2025 | Direct | |||
| Lynn Seely | LYEL | Option (right to buy) | Award | 175,000 | 175,000 | 27 Oct 2025 | Direct | |||
| Lynn Seely | LYEL | Common Stock | Sale | -9.7% | $76,518 | $10.54 | -7,257 | 67,571 | 21 Aug 2025 | Direct |
| Stephen J. Hill | LYEL | Common Stock | Sale | -5.96% | $10,586 | $10.54 | -1,004 | 15,845 | 21 Aug 2025 | Direct |
| Charles W. Newton | LYEL | Common Stock | Sale | -8.67% | $15,320 | $10.54 | -1,453 | 15,306 | 21 Aug 2025 | Direct |
| Gary K. Lee | LYEL | Common Stock | Sale | -8.57% | $15,320 | $10.54 | -1,453 | 15,504 | 21 Aug 2025 | Direct |
| Lynn Seely | LYEL | Common Stock | Award | 114.8% | 40,000 | 74,828 | 20 Aug 2025 | Direct | ||
| Stephen J. Hill | LYEL | Common Stock | Award | 90.4% | 8,000 | 16,849 | 20 Aug 2025 | Direct | ||
| Charles W. Newton | LYEL | Common Stock | Award | 91.3% | 8,000 | 16,759 | 20 Aug 2025 | Direct | ||
| Gary K. Lee | LYEL | Common Stock | Award | 89.3% | 8,000 | 16,957 | 20 Aug 2025 | Direct | ||
| Lynn Seely | LYEL | Common Stock | Sale | -1.15% | $4,197 | $10.34 | -406 | 34,828 | 12 Aug 2025 | Direct |
| Stephen J. Hill | LYEL | Common Stock | Sale | -1.05% | $972 | $10.34 | -94 | 8,849 | 12 Aug 2025 | Direct |
| Gary K. Lee | LYEL | Common Stock | Sale | -1.5% | $1,406 | $10.34 | -136 | 8,957 | 12 Aug 2025 | Direct |
| Charles W. Newton | LYEL | Common Stock | Sale | -1.53% | $1,406 | $10.34 | -136 | 8,759 | 12 Aug 2025 | Direct |
| Lynn Seely | LYEL | Common Stock | Sale | -1.1% | $4,116 | $10.53 | -391 | 35,234 | 11 Aug 2025 | Direct |
| Stephen J. Hill | LYEL | Common Stock | Sale | -1.01% | $958 | $10.53 | -91 | 8,943 | 11 Aug 2025 | Direct |
| Gary K. Lee | LYEL | Common Stock | Sale | -1.42% | $1,379 | $10.53 | -131 | 9,093 | 11 Aug 2025 | Direct |
| Charles W. Newton | LYEL | Common Stock | Sale | -1.45% | $1,379 | $10.53 | -131 | 8,895 | 11 Aug 2025 | Direct |
| Mark Bachleda | LYEL | Option (right to buy) | Award | 13,000 | 13,000 | 09 Jun 2025 | Direct | |||
| Mark A. Meltz | LYEL | Option (right to buy) | Award | 100,000 | 100,000 | 09 Jun 2025 | Direct | |||
| David Shook | LYEL | Common Stock | Award | 21,900 | 21,900 | 09 Jun 2025 | Direct | |||
| David Shook | LYEL | Option (right to buy) | Award | 43,750 | 43,750 | 09 Jun 2025 | Direct | |||
| Richard Klausner | LYEL | Option (right to buy) | Award | 130,000 | 130,000 | 15 May 2025 | Direct | |||
| William Jl Rieflin | LYEL | Option (right to buy) | Award | 130,000 | 130,000 | 15 May 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.